La vía ubiquitina-proteosoma como un nuevo objetivo para la prevención de la restenosis

Silke Meiners1, Michael Laule, Wim Rother

  • 1Medizinische Klinik und Poliklinik, Charité, Campus Mitte, Humboldt-Universität zu Berlin, Germany.

Circulation
|January 30, 2002
PubMed
Resumen

La inhibición del sistema ubiquitina-proteasoma reduce significativamente la restenosis vascular al disminuir la proliferación celular y la inflamación. Este estudio destaca el proteasoma como un nuevo objetivo terapéutico para prevenir la formación de neointima.

Videos de Conceptos Relacionados

Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...